Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
The DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders. Small intermediates - soluble oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insoluble deposits might function as reservoirs of the bioactive oligomers. These emerging concepts are exemplified by Alzheimer's disease, in which amyloid beta-protein oligomers adversely affect synaptic structure and plasticity. Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This observation suggests that oligodendrocytes could potentially generate a relatively higher proportion of longer Aβ species, which are more prone to aggregation [28]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“The increased Aβ 42:40 ratio in oligodendrocytes could contribute to the high proportion of soluble aggregates [28,42,43]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“and, consequently, could be more pathogenic than shorter Aβ species”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [8]
In the citing paper
“Dysregulation of A peptide metabolism is hypothesized to initiate pathogenic cascades that lead to Alzheimer's disease (AD) (Haass and Selkoe, 2007).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Haass and Selkoe, 2007
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Self-citationSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“These and other findings led to the formal proposal of a hypothesis of disease in which excessive Aβ accumulation and deposition could trigger a complex downstream cascade that resulted in the symptoms of A”
ResultRosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“In a similar manner, breakthrough discoveries of causative genes allowed the subsequent identification of aggregation-prone proteins in disorders such as amyotrophic lateral sclerosis (ALS”
ResultUbiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“More recently, TDP43 was found to be deposited in tau- and synuclein-negative inclusions in a disorder designated as frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) as well as in AL”
BackgroundGlenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Shortly thereafter, a distinct APP missense mutation was found in a family with early-onset A”
Background
Cited by
Items 1,001–1,100 of 1,119
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Park, H.-H., Lee, K.-Y., Kim, S., Lee, J. W., Choi, N.-Y., Lee, E.-H., Lee, Y. J., Lee, S.-H., & Koh, S.-H. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.015 · Cited by 72
Shim, H. S., Horner, J. W., Wu, C.-J., Li, J., Lan, Z. D., Jiang, S., Xu, X., Hsu, W.-H., Zal, T., Flores, I. I., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00146-z · Cited by 73
Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
Morales, R., Green, K., & Soto, C. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789541998 · Cited by 72
“However, the recent identification of oligomers as the most toxic species in both diseases [86–88] opens a new window to consider in the exploration and use of these therapeutic agents.”
Bulati, M., Buffa, S., Martorana, A., Gervasi, F., Camarda, C., Azzarello, D. M., Monastero, R., Caruso, C., & Colonna-Romano, G. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-142412 · Cited by 72
Kim, Y., Choi, H., Lee, W., Park, H., Kam, T.-I., Hong, S.-H., Nah, J., Jung, S., Shin, B., Lee, H., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.12.006 · Cited by 71
Oh, Y. K., Shin, K. S., Yuan, J., & Kang, S. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05053.x · Cited by 71
Guntupalli, S., Jang, S. E., Zhu, T., Huganir, R. L., Widagdo, J., & Anggono, V. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.774554 · Cited by 70
“At the cellular level, there is strong evidence that A is linked to a range of detrimental neurobiological processes, including reduced excitatory synaptic transmission, loss of dendritic spines, aberrant neuronal network activity, inflammation, and excitotoxic neuronal death (2, 4, 5).”
BackgroundAn Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?
Sciaccaluga, M., Megaro, A., Bellomo, G., Ruffolo, G., Romoli, M., Palma, E., & Costa, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115991 · Cited by 70
“Other studies demonstrate a strong correlation between the levels of soluble Aβ oligomers and the extent of synaptic deficit and the consequent severity of cognitive impairment [5,6].”
BackgroundThe Role of Cholesterol Metabolism in Alzheimer’s Disease
Sun, J.-H., Yu, J.-T., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8749-y · Cited by 70
The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration
Deger, J. M., Gerson, J. E., & Kayed, R. (2015) · Aging Cell · doi:10.1111/acel.12359 · Cited by 69
“Soluble Ab aggregates called oligomers have recently been suggested as the true toxic species (Haass & Selkoe, 2007), representing an intermediate in the early formation of larger deposits (Hoshi et al., 2003).”
BackgroundProtection against Aβ-mediated rapid disruption of synaptic plasticity and memory by memantine
Klyubin, I., Wang, Q., Reed, M. N., Irving, E. A., Upton, N., Hofmeister, J., Cleary, J. P., Anwyl, R., & Rowan, M. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.005 · Cited by 69
Quantitative analysis of co-oligomer formation by amyloid-beta peptide isoforms.
Iljina, M., Garcia, G. A., Dear, A. J., Flint, J., Narayan, P., Michaels, T. C. T., Dobson, C. M., Frenkel, D., Knowles, T. P. J., & Klenerman, D. (2016) · Scientific Reports · doi:10.1038/srep28658 · Cited by 68
Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer’s disease
Borin, M., Saraceno, C., Catania, M., Lorenzetto, E., Pontelli, V., Paterlini, A., Fostinelli, S., Avesani, A., Di Fede, G., Zanusso, G., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0567-4 · Cited by 68
Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease
Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66
“…histopathological, biomarker and animal model studies indicates that the 39–42 amino-acid (aa) peptide amyloidβ plays a prime role in the pathogenesis of familial and sporadic AD (Oddo et al., 2003; Haass and Selkoe, 2007; Bertram et al., 2010; Jack et al., 2010, 2013; Bateman et al., 2012).”
BackgroundSorting receptor SORLA: cellular mechanisms and implications for disease
Schmidt, V., Subkhangulova, A., & Willnow, T. E. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2410-z · Cited by 65
“Amyloid-b peptides, notably Ab42, are considered main culprits in neurodegenerative processes as they exhibit a tendency to aggregate to neurotoxic oligomers and senile plaques, pathological features causative of neuronal dysfunction and cell loss in AD patients (reviewed in [27]).”
Backgroundde Oliveira, J., Moreira, E. L. G., dos Santos, D. B., Piermartiri, T. C., Dutra, R. C., Pinton, S., Tasca, C. I., Farina, M., Prediger, R. D. S., & de Bem, A. F. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132228 · Cited by 62
“The main 40 less abundant 42-amino-acid form (A (cid:1) 42 ) is more amyloidogenic [10].”
Colombo, A., Wang, H., Kuhn, P.-H., Page, R., Kremmer, E., Dempsey, P. J., Crawford, H. C., & Lichtenthaler, S. F. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.08.011 · Cited by 62
“A central player in AD pathogenesis is the amyloid β peptide (Aβ), which forms toxic oligomeric aggregates leading to neurodegeneration (for review see Hardy and Selkoe, 2002; Haass and Selkoe, 2007; Laferla et al., 2007).”
BackgroundUBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation
Subramanian, M., Hyeon, S. J., Das, T., Suh, Y. S., Kim, Y. K., Lee, J.-S., Song, E. J., Ryu, H., & Yu, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23597-9 · Cited by 62
Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
Antonios, G., Borgers, H., Richard, B. C., Brauß, A., Meißner, J., Weggen, S., Pena, V., Pillot, T., Davies, S. L., Bakrania, P., et al. (2015) · Scientific Reports · doi:10.1038/srep17338 · Cited by 61
Wang, Z., Liu, J., Han, J., Zhang, T., Li, S., Hou, Y., Su, H., Han, F., & Zhang, C. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03166-9 · Cited by 60
Campos-Peña, V., Toral-Rios, D., Becerril-Pérez, F., Sánchez-Torres, C., Delgado-Namorado, Y., Torres-Ossorio, E., Franco-Bocanegra, D., & Carvajal, K. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6768 · Cited by 58
“2) (108).”
The Emerging Role of Altered Cerebellar Synaptic Processing in Alzheimer’s Disease
Hoxha, E., Lippiello, P., Zurlo, F., Balbo, I., Santamaria, R., Tempia, F., & Miniaci, M. C. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00396 · Cited by 58
“Further studies in APP23 transgenic mice have shown that degeneration of LC results in elevated Aβ deposition and increased neuroinflammation in brain areas usually innervated by LC (Heneka et al., 2010).”
BackgroundSynergistic Inhibitory Effect of GQDs–Tramiprosate Covalent Binding on Amyloid Aggregation
Liu, Y., Xu, L.-P., Wang, Q., Yang, B., & Zhang, X. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00439 · Cited by 58
Zhang, Y., Zhao, Y., Zhang, L., Yu, W., Wang, Y., & Chang, W. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00339 · Cited by 58
“A variety of other assemblies including Aβ protofibrils and soluble oligomers of various sizes have also been identified (Caughey and Lansbury, 2003; Haass and Selkoe, 2007).”
BackgroundRhein, V., & Eckert, A. (2007) · Archives of Physiology and Biochemistry · doi:10.1080/13813450701572288 · Cited by 56
Lilja, A. M., Porras, O., Storelli, E., Nordberg, A., & Marutle, A. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101242 · Cited by 57
“Mounting evidence suggests that oligomeric forms of A may be the major contributors to impairment of synaptic and cognitive functions in AD [6, 7].”
Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA.
Pizzo, M. E., Plowey, E. D., Khoury, N., Kwan, W., Abettan, J., DeVos, S. L., Discenza, C. B., Earr, T., Joy, D., Lye-Barthel, M., et al. (2025) · Science · doi:10.1126/science.ads3204 · Cited by 63
Chakrabarti, M., McDonald, A. J., Will Reed, J., Moss, M. A., Das, B. C., & Ray, S. K. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150450 · Cited by 57
“Aβ peptides originate from proteolysis of amyloid-β precursor protein (AβPP) by the sequential enzymatic actions of β-site amyloid precursor protein cleaving enzyme 1 (BACE-1), βsecretase and γ-secretase, a protein complex with presenilin 1 (PS1) at its catalytic core [1, 3, 5, 6].”
Rajani, R. M., Ellingford, R., Hellmuth, M., Harris, S. S., Taso, O. S., Graykowski, D., Lam, F. K. W., Arber, C., Fertan, E., Danial, J. S. H., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002727 · Cited by 62
“This observation suggests that oligodendrocytes could potentially generate a relatively higher proportion of longer A β species, which are more prone to aggregation [28] and, consequently, could be more pathogenic than shorter A β species.”
BackgroundHascup, K. N., & Hascup, E. R. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160041 · Cited by 57
“This process, referred to as the amyloid cascade hypothesis, proposes that A (cid:2) initiates the series of pathological events leading to neuronal dysfunction, cell death, and the eventual cognitive impairments observed in AD [2].”
Nicholls, R. E., Sontag, J.-M., Zhang, H., Staniszewski, A., Yan, S., Kim, C. Y., Yim, M., Woodruff, C. M., Arning, E., Wasek, B., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521018113 · Cited by 56
Back and forth in time: Directing age in iPSC-derived lineages
Cornacchia, D., & Studer, L. (2017) · Brain Research · doi:10.1016/j.brainres.2015.11.013 · Cited by 56
“Parkinsonian brains from familial or sporadic forms of PD are characterized by the appearance of distinctive cellular inclusions known as Lewy bodies, which contain aberrant aggregates of α-synuclein and ubiquitin (Polymeropoulos et al., 1996; Haass and Selkoe, 2007).”
Matrix Metalloproteinases and Their Multiple Roles in Alzheimer's Disease
Wang, X.-X., Tan, M.-S., Yu, J.-T., & Tan, L. (2014) · BioMed Research International · doi:10.1155/2014/908636 · Cited by 55
“It has been suggested that soluble oligomeric Aβ correlates better with dementia than insoluble fibrillar deposits, indicating that oligomeric Aβ may represent the primary toxic species in AD [13].”
Li, S., Yan, Y., Jiao, Y., Gao, Z., Xia, Y., Kong, L., Yao, Y., Tao, Z., Song, J., Yan, Y., et al. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0793-9 · Cited by 55
“3c, d), which acts as a neurotoxic oligomer (Haass and Selkoe 2007; Schonrock et al. 2010).”
Perea, J. R., Ávila, J., & Bolós, M. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.08.007 · Cited by 54
Antonios, G., Saiepour, N., Bouter, Y., Richard, B. C., Paetau, A., Verkkoniemi-Ahola, A., Lannfelt, L., Ingelsson, M., Kovacs, G. G., Pillot, T., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-56 · Cited by 53
“Mori H, Takio K, Ogawara M, Selkoe DJ: Mass spectrometry of purified amyloid beta protein in Alzheimer's disease.”
BackgroundInfluentialSaleem, U., Akhtar, R., Anwar, F., Shah, M. A., Chaudary, Z., Ayaz, M., & Ahmad, B. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00683-x · Cited by 53
Tau acts as a mediator forAlzheimer's disease‐related synaptic deficits
Liao, D., Miller, E. C., & Teravskis, P. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12504 · Cited by 53
“…Ab1–42 on synapses, and the findings have reframed the amyloid hypothesis to focus upon soluble Ab oligomers (also more descrip- tively referred to as Ab-derived diffusible ligands or Ab microaggregates), rather than neuritic plaques (Haass & Selkoe, 2007; Krafft & Klein, 2010; Sheng et al., 2012).”
BackgroundQuantum Dots as A Theranostic Approach in Alzheimer’s Disease: A Systematic Review
Villalva, M. D., Agarwal, V., Ulanova, M., Sachdev, P. S., & Braidy, N. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0104 · Cited by 53
ACAT inhibition and amyloid beta reduction
Bhattacharyya, R., & Kovacs, D. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.04.003 · Cited by 53
Abelein, A., Ciofi-Baffoni, S., Mörman, C., Kumar, R., Giachetti, A., Piccioli, M., & Biverstål, H. (2022) · JACS Au · doi:10.1021/jacsau.2c00438 · Cited by 52
Jha, R. R., Singh, C., Pant, A. B., & Patel, D. K. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2017.12.015 · Cited by 51
Chernick, D., Ortiz‐Valle, S., Jeong, A., Swaminathan, S. K., Kandimalla, K. K., Rebeck, G. W., & Li, L. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14554 · Cited by 51
Modulation of the Aβ peptide aggregation pathway by KP1019 limits Aβ-associated neurotoxicity
Jones, M. R., Mu, C., Wang, M. C. P., Webb, M. I., Walsby, C. J., & Storr, T. (2015) · Metallomics · doi:10.1039/c4mt00252k · Cited by 50
Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
Seripa, D., Solfrizzi, V., Imbimbo, B. P., Daniele, A., Santamato, A., Lozupone, M., Zuliani, G., Greco, A., Logroscino, G., & Panza, F. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1140039 · Cited by 50
“ture and plasticity, [53] and a broadly similar process of neuronal dysfunction is induced by some intermediate hyperphosphorylated, most likely soluble, tau species”
BackgroundBraymer, J. J., DeToma, A. S., Choi, J.-S., Ko, K. S., & Lim, M. H. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/623051 · Cited by 50
“Current evidence suggests that monomers and fibrils are relatively benign, while soluble oligomers, including dimers, are responsible for the neurotoxicity leading to dementia [8, 9].”
BackgroundTwo Functions, One Molecule: A Metal‐Binding and a Targeting Moiety to Combat Alzheimer's Disease
Hureau, C., Sasaki, I., Gras, E., & Faller, P. (2010) · ChemBioChem · doi:10.1002/cbic.201000102 · Cited by 49
Stark, D. T., & Bazan, N. G. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8174-4 · Cited by 49
“The oligomer accumulates as an aggregate and becomes a major component of senile plaques [26–31].”
BackgroundSynaptic contact number and size in stratum radiatum CA1 of APP/PS1ΔE9 transgenic mice
West, M. J., Bach, G., Søderman, A., & Jensen, J. L. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.01.009 · Cited by 48
Petrushina, I., Hovakimyan, A., Harahap-Carrillo, I. S., Davtyan, H., Antonyan, T., Chailyan, G., Kazarian, K., Antonenko, M., Jullienne, A., Hamer, M. M., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104823 · Cited by 48
“This hypothesis is focused on soluble oligomers and protofibrils of Aβ, which are now considered to be the most toxic forms of Aβ, responsible for synaptic destruction (Cleary et al., 2005; Cline et al., 2018; Haass and Selkoe, 2007; Klein et al., 2004; Lacor et al., 2007; Lambert et al., 1998; Shankar et al., 2007; S…”
Sharma, A. K., Kim, J., Prior, J. T., Hawco, N. J., Rath, N. P., Kim, J., & Mirica, L. M. (2014) · Inorganic Chemistry · doi:10.1021/ic500926c · Cited by 53
Sharma, S., Nehru, B., & Saini, A. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.06.011 · Cited by 48
“Ab 42 peptide has very high tendency to form aggregates and it starts aggregating as soon as it gets an aqueous media (Haass and Selkoe, 2007).”
BackgroundExpression of the Anti-amyloidogenic Secretase ADAM10 Is Suppressed by Its 5′-Untranslated Region
Lammich, S., Buell, D., Zilow, S., Ludwig, A.-K., Nuscher, B., Lichtenthaler, S. F., Prinzen, C., Fahrenholz, F., & Haass, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.110742 · Cited by 48
Self-citationTraditional used Plants against Cognitive Decline and Alzheimer Disease
Eckert, G. P. (2010) · Frontiers in Pharmacology · doi:10.3389/fphar.2010.00138 · Cited by 47
“…on two key neuropathological hallmarks, namely the hyperphosphorylation of the tau protein resulting in the formation of neurofibrillary tangles (NFTs), and the increased formation and aggregation of amyloid-beta peptide (Aβ) derived from amyloid precursor protein (APP) (Haass and Selkoe, 2007).”
BackgroundInfluentialGatson, J. W., Warren, V., Abdelfattah, K., Wolf, S., Hynan, L. S., Moore, C., Diaz-Arrastia, R., Minei, J. P., Madden, C., & Wigginton, J. G. (2013) · Journal of Neurosurgery · doi:10.3171/2013.2.jns121771 · Cited by 47
Mosconi, L., Glodzik, L., Mistur, R., McHugh, P., Rich, K. E., Javier, E., Williams, S., Pirraglia, E., De Santi, S., Mehta, P. D., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.011 · Cited by 46
“Although the causal relationship between Aβ, oxidative stress and tau pathology remains to be clarified, Aβ may lead to NFT formation within cells (30,31), and NFT-containing neurons also show extensive evidence for oxidative stress (28).”
BackgroundResultInfluentialLi, S.-H., Gao, P., Wang, L.-T., Yan, Y.-H., Xia, Y., Song, J., Li, H.-Y., & Yang, J.-X. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00340 · Cited by 46
“RT-PCR and Western blot (Figures 2B,C) revealed the abundant expression of APP, which gives rise to the Aβ, as a neurotoxic oligomer (Haass and Selkoe, 2007; Schonrock et al., 2010b).”
BackgroundMeilandt, W. J., Maloney, J. A., Imperio, J., Lalehzadeh, G., Earr, T., Crowell, S., Bainbridge, T. W., Lu, Y., Ernst, J. A., Fuji, R. N., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0553-5 · Cited by 45
Suelves, N., Saleki, S., Ibrahim, T., Palomares, D., Moonen, S., Koper, M. J., Vrancx, C., Vadukul, D. M., Papadopoulos, N., Viceconte, N., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01578-x · Cited by 43
“The accumulation of the Aβ peptide is an early event that initiates AD pathophysiology [42, 45, 46].”
BackgroundRönnbäck, A., Sagelius, H., Bergstedt, K. D., Näslund, J., Westermark, G. T., Winblad, B., & Graff, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.07.012 · Cited by 43
Hirohata, M., Ono, K., Takasaki, J.-I., Takahashi, R., Ikeda, T., Morinaga, A., & Yamada, M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.05.006 · Cited by 43
Tong, H., Zhang, X., Meng, X., Xu, P., Zou, X., & Qu, S. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.01.017 · Cited by 42
Specific Domains of Aβ Facilitate Aggregation on and Association with Lipid Bilayers
Yates, E. A., Owens, S. L., Lynch, M. F., Cucco, E. M., Umbaugh, C. S., & Legleiter, J. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.03.022 · Cited by 41
Hong, I., Kang, T., Yoo, Y., Park, R., Lee, J., Lee, S., Kim, J., Song, B., Kim, S.-Y., Moon, M., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130311 · Cited by 41
An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42
Dafnis, I., Stratikos, E., Tzinia, A., Tsilibary, E. C., Zannis, V. I., & Chroni, A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06756.x · Cited by 41
“42-amino-acid Ab variant (Ab42) has been found to be more prone to fibril formation and more closely associated with the pathogenesis of AD than shorter Ab forms (Haass and Selkoe 2007).”
BackgroundMethodInfluentialSynthesis and characterization of IMPY derivatives that regulate metal-induced amyloid-β aggregation
Choi, J.-S., Braymer, J. J., Park, S. K., Mustafa, S., Chae, J., & Lim, M. H. (2011) · Metallomics · doi:10.1039/c0mt00077a · Cited by 41
Ajmo, J. M., Bailey, L. A., Howell, M. D., Cortez, L. K., Pennypacker, K. R., Mehta, H. N., Morgan, D., Gordon, M. N., & Gottschall, P. E. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06647.x · Cited by 41
Mosconi, L., (ADNI), F. T. A. D. N. I., Andrews, R. D., & Matthews, D. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-121867 · Cited by 41
“Currently available evidence supports the position that an abnormal processing of A peptide, ultimately leading to formation of A plaques in the brain, is the initiating event in AD [57].”
Amyloid‐β induces sleep fragmentation that is rescued by fatty acid binding proteins in Drosophila
Gerstner, J. R., Lenz, O., Vanderheyden, W. M., Chan, M. T., Pfeiffenberger, C., & Pack, A. I. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23778 · Cited by 40
A Promising Approach: Magnetic Nanosystems for Alzheimer’s Disease Theranostics
Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092316 · Cited by 40
“Although almost 90% of the residues consist of Aβ40, the Aβ42 is the most abundant isoform for amyloid plaque development and leads to augmented neurotoxic effects [7,9,10].”
BackgroundDynamic Blood Concentrations of Aβ1–40 and Aβ1–42 in Alzheimer’s Disease
Yang, Y.-H., Huang, L.-C., Hsieh, S.-W., & Huang, L.-J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00768 · Cited by 39
“…by the cleavage of amyloid precursor proteins into a monomeric form with peptides of different lengths by β-secretase and γ-secretase, which is then transformed into oligomeric and fibril forms, and eventually into amyloid plaques (Haass and Selkoe, 2007; Tapiola et al., 2009) in brain tissue.”
BackgroundGDE2-RECK controls ADAM10 α-secretase–mediated cleavage of amyloid precursor protein
Nakamura, M., Li, Y., Choi, B.-R., Matas-Rico, E., Troncoso, J., Takahashi, C., & Sockanathan, S. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe6178 · Cited by 38
Reactivity of Diphenylpropynone Derivatives Toward Metal-Associated Amyloid-β Species
Pithadia, A. S., Kochi, A., Soper, M. T., Beck, M. W., Liu, Y., Lee, S., DeToma, A. S., Ruotolo, B. T., & Lim, M. H. (2012) · Inorganic Chemistry · doi:10.1021/ic302084g · Cited by 38
Evidence for aggregation-independent, PrP C -mediated Aβ cellular internalization
Foley, A. R., Roseman, G. P., Chan, K., Smart, A., Finn, T. S., Yang, K., Lokey, R. S., Millhauser, G. L., & Raskatov, J. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009238117 · Cited by 38
Song, N., Zhang, L., Chen, W., Zhu, H., Deng, W., Han, Y., Guo, J., & Qin, C. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.05.016 · Cited by 36
Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention
Rafii, M. S., & Aisen, P. S. (2019) · CNS Drugs · doi:10.1007/s40263-018-0598-1 · Cited by 36
Llano, D. A., Devanarayan, P., & Devanarayan, V. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000328 · Cited by 35
Palmer, A., & Good, M. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390902 · Cited by 34
Liquid-liquid phase separation in Alzheimer’s disease
Fu, Q., Zhang, B., Chen, X., & Chu, L. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02407-3 · Cited by 33
“The non-amyloidogenic cleavage pathway is triggered by α-secretase, whereas the amyloidogenic pathway is initiated by β-secretase. γ-Secretase is used to process the remaining membrane-bound fragments generated by these two pathways [68, 127, 128].”
Song, M.-S., Learman, C. R., Ahn, K.-C., Baker, G. B., Kippe, J., Field, E. M., & Dunbar, G. L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.011 · Cited by 33
“Our study supports the findings in previous studies showing that oligomeric Ab is a key driver important for AD pathogenesis in early stages of the disease (Walsh et al., 2002; Haass and Selkoe, 2007; Freir et al., 2011; Li et al., 2011).”
BackgroundResultTakeda, K., Uda, A., Mitsubori, M., Nagashima, S., Iwasaki, H., Ito, N., Shiiba, I., Ishido, S., Matsuoka, M., Inatome, R., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01720-2 · Cited by 32
Sun, L., Liu, D., Fu, D., Yue, T., Scharre, D., & Zhang, L. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.126733 · Cited by 32
Dafnis, I., Tzinia, A. K., Tsilibary, E. C., Zannis, V. I., & Chroni, A. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.013 · Cited by 32
Baydargil, H. B., Park, J.-S., & Kang, D.-Y. (2021) · Applied Sciences · doi:10.3390/app11052187 · Cited by 30
Murakami, K., & Irie, K. (2019) · Molecules · doi:10.3390/molecules24112125 · Cited by 31
Tikhonova, M. A., Amstislavskaya, T. G., Belichenko, V. M., Fedoseeva, L. A., Kovalenko, S. P., Pisareva, E. E., Avdeeva, A. S., Kolosova, N. G., Belyaev, N. D., & Aftanas, L. I. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0412-5 · Cited by 30
“Oligomeric Aβ species represent the most toxic forms causing impaired synaptic and neuronal functions [4, 5].”
Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer’s Disease
Ganeshpurkar, A., Swetha, R., Kumar, D., Gangaram, G. P., Singh, R., Gutti, G., Jana, S., Kumar, D., Kumar, A., & Singh, S. K. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304153353 · Cited by 30
Ou-Yang, M.-H., & Van Nostrand, W. E. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-134 · Cited by 30
“© 2013 Ou-Yang and Van Nostrand; licensee B the Creative Commons Attribution License (ht distribution, and reproduction in any medium [5,6].”
BackgroundReelin reverts biochemical, physiological and cognitive alterations in mouse models of Tauopathy
Rossi, D., Gruart, A., Contreras-Murillo, G., Muhaisen, A., Ávila, J., Delgado-García, J. M., Pujadas, L., & Soriano, E. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101743 · Cited by 30
“Although Aβ oligomers have been widely recognized as the main species responsible for synaptic dysfunction in AD [16-18], recent data indicate that their toxicity is mediated by Tau protein [19-21], whose intracellular aggregates, known as neurofibrillary tangles (NFTs), are another hallmark of the disease.”
BackgroundSex-Dependent Differences in Spontaneous Autoimmunity in Adult 3xTg-AD Mice
Kapadia, M., Mian, M. F., Michalski, B., Azam, A. B., Ma, D., Salwierz, P., Christopher, A., Rosa, E., Zovkic, I. B., Forsythe, P., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-170779 · Cited by 29
“Althoughsexdifferenceswereoriginallydescribed in plaque-bearing 3xTg-AD mice [21], there is a growing consensus that neuronal dysfunction in AD is triggered by soluble species, rather than insoluble tangles and plaques [28, 29].”
Sonic hedgehog signalling pathway contributes in age-related disorders and Alzheimer’s disease
Parashar, A., jha, D., Mehta, V., Chauhan, B., Ghosh, P., Deb, P. K., Jaiswal, M., & Prajapati, S. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102271 · Cited by 28
Monomeric Aβ1–42 and RAGE: key players in neuronal differentiation
Piras, S., Furfaro, A. L., Piccini, A., Passalacqua, M., Borghi, R., Carminati, E., Parodi, A., Colombo, L., Salmona, M., Pronzato, M. A., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.002 · Cited by 27
“(Haass and Selkoe, 2007; Kayed et al., 2003; Piccini et al., 2005; Selkoe, 2003).”
Hu, T., Wang, S., Chen, C., Sun, J., & Yang, X. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04950 · Cited by 28
Current therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30
Reinke, A. A., Seh, H. Y., & Gestwicki, J. E. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.07.082 · Cited by 26
Tsunoda, T., Takase, M., & Shigemori, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.04.044 · Cited by 26
Differential processing of amyloid precursor protein in brain and in peripheral blood leukocytes
Delvaux, E., Bentley, K., Stubbs, V., Sabbagh, M., & Coleman, P. D. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.004 · Cited by 26
“…of amyloid precursor protein (APP) play a central role in the pathophysiology of Alzheimer’s disease (Hardy and Selkoe, 2002; Walsh et al., 2005; Haass and Selkoe, 2007; Shankar et al., 2007; Palop and Mucke 2010; Lublin and Gandy, 2010; Shimada et al., 2011; Jonsson et al., 2012), and are…”
BackgroundTaneo, J., Adachi, T., Yoshida, A., Takayasu, K., Takahara, K., & Inaba, K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.006 · Cited by 25
Funakoshi, H., & Nakamura, T. (2011) · Current Signal Transduction Therapy · doi:10.2174/157436211795659982 · Cited by 23
Metadata
- Authors
- Haass, C., & Selkoe, D. J.
- Affiliations
- Adolf-Butenandt-Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie (DE)
- Venue
- Nature Reviews Molecular Cell Biology
- Published
- 2007-02
- Volume
- 8
- Issue
- 2
- Pages
- 101-112
- ISSN
- 1471-0072 (ISSN-L)
- 1471-0080
- OpenAlex
- W1980825524
- Cited by
- 4,744
- References
- 135
- Citations by year
- 2026: 135 · 2025: 171 · 2024: 165 · 2023: 170 · 2022: 195 · 2021: 239 · 2020: 273 · 2019: 247 · 2018: 276 · 2017: 290 · 2016: 331 · 2015: 313 · 2014: 285 · 2013: 307 · 2012: 327
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Molecular Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neurodegeneration, protein misfolding, protein aggregation, synaptic dysfunction, synaptic plasticity, Parkinson's disease, Huntington's disease, prion disease, neuronal dysfunction
- MeSH terms
- Alzheimer Disease, Cell Membrane, Humans, Memory Disorders, Models, Biological, Nerve Degeneration, Solubility, Synapses, Signal Transduction, Amyloid beta-Peptides, Protein Folding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.